More than 30 years of being in business have put Singapore-listed Medtecs International in exceptional stead this Covid year.

That's why the Singapore government has been one of its top customers this year along with the Taiwan government.

WilliamYang11.20 wideTaiwan-based Medtecs CEO William Yang on an earnings call today.These countries have for many years sourced personal protective equipment (PPE) for their national stockpiles from Medtecs.

Medtecs, manufacturing out of Cambodia and the Philippines, says it is the largest PPE producer outside of China.

Medtecs gross profit margin







Yes, selling prices for its products (PPE and masks) have eased since peaking in April this year.

Currently, they are "stable" with attractive gross margins because raw material prices have pulled back sharply, and because Medtecs now sells directly to global buyers, said Medtecs CEO William Yang at an earnings call today (10 Nov).

"Even though ASPs have dropped, they have stabilised, our gross profit percentage is still high and we are getting more and more market share."

Medtecs BizModel

This year has been exceptional in that Medtecs has attracted many new long-term customers, and
business volume is looking to grow, said Mr Yang on a 3Q results earnings call.

In fact, possibly, Medtecs will have to expand production capacity.   

Stock price 


52-week range

3 c – $1.98

Market cap

S$560 m

PE (FY20F)*

less than 3.2x

Dividend yield 


1-year return


Shares outstanding

549.4 m

* assumes at least S$175 m profit in FY20, based on company guidance of "record profit" in 4Q.

In Cambodia, where it produces PPE, it has unutilised land to expand production facilities on, and it can tap skilled labour which has been recently laid off by garment factories.

"We'll review the necessity to ramp up our in-house capacity. B
ut as you know, if the orders are big and for the long term, then why not do it in-house?

Customers usually order 2-3 months in advance of delivery but they also give Medtecs order forecasts for the rolling 6-12 months.

"For 2021, with or without Covid vaccine, our customers’ demand is increasing and our market, our orders are just growing," said Mr Yang. 

In the US, Medtecs will soon open its initial facility producing masks (branded Medtecs) to tap into demand arising from the President-elect's emphasis on mask-wearing.

Capex for further expansion will be well supported by the large cashflow and profitability this year.

(Based on earlier guidance, Medtecs's 4Q will be at least as strong as 3Q. In other words, the company is set to report at least US$129 million net profit this year)

"With long-term indicative orders in hand and stabilizing raw material prices, the Company expects to report record revenue and profit in the fourth quarter and financial year ending 31 December 2020." -- Medtecs (13 Oct 2020)


Net profit (USD)




4Q20 (assumed)

FY20 (assumed)

US$3.7 m

US$35 m

US$45 m

US$45 m

US$129 m (minimum)


Medtecs CoverU 11.20Front-line healthcare workers in a UK hospital donning Medtecs' PPE branded CoverU. Photo: The Telegraph
This year happens also to be the year Medtecs pivoted to a far more profitable business model. 

It created its own brand and sold directly to the world, moving away from doing OEM and selling to middlemen as in past years.

Thus its gross margins, especially starting from 2Q, have expanded along with the higher average selling prices (ASPs) lifted by Covid-induced demand. 

Based on the company's announcements, 2Q gross margin was 36%, increasing to 53% in 3Q. 

"For the future, we will have hundreds of hospitals buying directly from us. Now they can talk to the brand owner, to the manufacturer directly and we can develop products according to their needs," said Mr Yang.

Medtecs' corporate presentation is here. 

You may also be interested in:


#3 Benni 2020-11-16 20:15
The competitive edge of Medtecs is worth pointing out. As PPE is used up by clients, especially national stockpiles, the next wave of orders is automatic. There are high barriers of entry for quality PPEs that are not appreciated by investors, so their revenue continues to roll on with momentum!
#2 Steph 2020-11-11 11:12
I always take management's words with a pinch of salt - 99% of CEOs always sugar-coat their words.
#1 BOD 2020-11-11 09:11
MT has capabilities as end to end supplier for hospitals. This is a game changer for more sustainable growth. Hospitals like to deal with reputed and certified suppliers and if one supplier can assure on time supply and quality at competitive price it is a big moat. I believe MT is getting there.

You have no rights to post comments

Counter NameLastChange
AEM Holdings1.850-0.010
Best World2.490-0.010
Boustead Singapore0.9550.005
Broadway Ind0.1580.010
China Aviation Oil (S)0.8750.005
China Sunsine0.400-
Delfi Limited0.8800.005
Food Empire1.110-
Fortress Minerals0.295-
Geo Energy Res0.305-
Hong Leong Finance2.430-0.010
Hongkong Land (USD)3.450-0.050
ISDN Holdings0.3100.005
IX Biopharma0.040-
KSH Holdings0.250-
Leader Env0.049-
Ley Choon0.0550.001
Marco Polo Marine0.0680.001
Mermaid Maritime0.138-
Nordic Group0.295-0.010
Oxley Holdings0.0880.001
REX International0.125-0.001
Southern Alliance Mining0.485-
Straco Corp.0.480-
Sunpower Group0.220-
The Trendlines0.063-
Totm Technologies0.019-0.001
Uni-Asia Group0.800-0.010
Wilmar Intl3.1400.010
Yangzijiang Shipbldg1.730-0.010

We have 2291 guests and no members online

rss_2 NextInsight - Latest News